2.53
0.02 (0.80%)
| Previous Close | 2.51 |
| Open | 2.54 |
| Volume | 3,946,345 |
| Avg. Volume (3M) | 3,656,100 |
| Market Cap | 858,335,424 |
| Price / Sales | 53.70 |
| Price / Book | 1.60 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Operating Margin (TTM) | -1,913.23% |
| Diluted EPS (TTM) | -2.20 |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 9.01 |
| Operating Cash Flow (TTM) | -157.34 M |
| Levered Free Cash Flow (TTM) | -64.76 M |
| Return on Assets (TTM) | -23.33% |
| Return on Equity (TTM) | -119.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Nuvation Bio Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.5 |
| Average | 0.20 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.14% |
| % Held by Institutions | 61.81% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 31 Mar 2025 | 25,954,439 |
| Omega Fund Management, Llc | 31 Mar 2025 | 13,072,340 |
| Laurion Capital Management Lp | 31 Mar 2025 | 9,871,077 |
| Mpm Bioimpact Llc | 31 Mar 2025 | 4,652,243 |
| Tang Capital Management Llc | 31 Mar 2025 | 3,900,000 |
| Aisling Capital Management Lp | 31 Mar 2025 | 2,541,009 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 6.00 (RBC Capital, 137.15%) | Buy |
| 6.00 (JMP Securities, 137.15%) | Buy | |
| Median | 6.00 (137.15%) | |
| Low | 5.00 (Wedbush, 97.63%) | Buy |
| Average | 5.67 (124.11%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 1.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 25 Jun 2025 | 6.00 (137.15%) | Buy | 1.97 |
| 02 Jun 2025 | 6.00 (137.15%) | Buy | 2.34 | |
| RBC Capital | 17 Jun 2025 | 6.00 (137.15%) | Buy | 1.71 |
| Wedbush | 11 Jun 2025 | 5.00 (97.63%) | Buy | 2.20 |
| 16 May 2025 | 5.00 (97.63%) | Buy | 2.26 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HUNG DAVID | 1.86 | - | 500,000 | 930,000 |
| MARKEL STACY | 1.79 | - | 10,000 | 17,900 |
| SAUVAGE PHILIPPE | 1.79 | - | 7,300 | 12,978 |
| SJOGREN COLLEEN | 1.86 | - | 50,000 | 93,000 |
| WENTWORTH KERRY | 1.86 | - | 50,000 | 93,000 |
| Aggregate Net Quantity | 617,300 | |||
| Aggregate Net Value ($) | 1,146,878 | |||
| Aggregate Avg. Buy ($) | 1.82 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MARKEL STACY | Officer | 18 Jun 2025 | Buy (+) | 10,000 | 1.79 | 17,900 |
| SAUVAGE PHILIPPE | Officer | 17 Jun 2025 | Buy (+) | 4,000 | 1.71 | 6,840 |
| HUNG DAVID | Officer | 16 Jun 2025 | Buy (+) | 500,000 | 1.86 | 930,000 |
| WENTWORTH KERRY | Officer | 16 Jun 2025 | Buy (+) | 50,000 | 1.86 | 93,000 |
| SAUVAGE PHILIPPE | Officer | 16 Jun 2025 | Buy (+) | 3,300 | 1.86 | 6,138 |
| SJOGREN COLLEEN | Officer | 16 Jun 2025 | Buy (+) | 50,000 | 1.86 | 93,000 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |